Nishizawa Y, Morii H, Ogura Y, De Luca H F
Second Department of Internal Medicine, Osaka City University Medical School, Japan.
Contrib Nephrol. 1991;90:196-203. doi: 10.1159/000420143.
A clinical trial was done by the Group, Japan to evaluate the efficacy of 26,27-F6-1,25(OH)2D3 on the calcium and bone metabolism of 43 uremic patients on hemodialysis, 24 men and 19 women with a mean age of 50.9 +/- 2.1 years. The initial dose administered orally was 0.05 micrograms/day for 2 weeks. Then the dose was increased every 2 weeks by 0.05 micrograms each time until the dose of 0.3 micrograms/day was reached or until serum calcium increased. 26,27-F6(OH)2D3 increased serum calcium levels significantly at a mean dose of 0.08 +/- 0.03 micrograms/day and at 0.05 micrograms/day of dose comparison in hemodialyzed patients. It decreased the serum level of PTH significantly at a mean dose of 0.14 +/- 0.06 micrograms/day and at 0.3 micrograms/day by dose comparison. The serum level of bone Gla protein increased significantly at a mean dose of 0.18 +/- 0.07 micrograms/day and at 0.25 micrograms/day by dose comparison in the same patients. These results suggest that 26,27-F6-1,25(OH)2D3 has a higher potency in calcium mobilization than 1,25(OH)2D3 in uremic patients on hemodialysis.
日本的该研究小组进行了一项临床试验，以评估26,27-F6-1,25(OH)2D3对43例接受血液透析的尿毒症患者钙和骨代谢的疗效，其中男性24例，女性19例，平均年龄为50.9±2.1岁。口服初始剂量为0.05微克/天，持续2周。然后每2周剂量每次增加0.05微克，直至达到0.3微克/天的剂量或血清钙升高。在血液透析患者中，26,27-F6(OH)2D3在平均剂量为0.08±0.03微克/天以及剂量对比为0.05微克/天时可显著提高血清钙水平。通过剂量对比，在平均剂量为0.14±0.06微克/天以及剂量为0.3微克/天时，它可显著降低血清甲状旁腺激素水平。在同一批患者中，通过剂量对比，骨钙素血清水平在平均剂量为0.18±0.07微克/天以及剂量为0.25微克/天时显著升高。这些结果表明，在接受血液透析的尿毒症患者中，26,27-F6-1,25(OH)2D3在钙动员方面比1,25(OH)2D3具有更高的效力。
